StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)

Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –

Zevra Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Zevra Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $82.38M. For fiscal 2025 it was -$62.94M. The highest annual figure on record is $7.73M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$62.94M–
FY2024Dec 31, 2024-$87.00M–
FY2023Dec 31, 2023-$49.60M–
FY2022Dec 31, 2022-$42.57M-650.7%
FY2021Dec 31, 2021$7.73M–
FY2020Dec 31, 2020-$5.61M–
FY2019Dec 31, 2019-$20.34M–
FY2018Dec 31, 2018-$55.90M–
FY2017Dec 31, 2017-$33.37M–
FY2016Dec 31, 2016-$37.48M–
FY2015Dec 31, 2015-$22.81M–
FY2014Dec 31, 2014-$16.44M–
FY2013Dec 31, 2013-$4.72M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$16.78M–
Q1 FY2026Mar 31, 2026$52.15M–
Q4 FY2025Dec 31, 2025$9.32M–
Q3 FY2025Sep 30, 2025$4.14M–
Q2 FY2025Jun 30, 2025-$71.04M–
Q1 FY2025Mar 31, 2025-$5.36M–
Q4 FY2024Dec 31, 2024-$15.42M–
Q3 FY2024Sep 30, 2024-$27.31M–
Q2 FY2024Jun 30, 2024-$23.80M–
Q1 FY2024Mar 31, 2024-$20.49M–
Q4 FY2023Dec 31, 2023-$15.16M–
Q3 FY2023Sep 30, 2023-$15.36M–
Q2 FY2023Jun 30, 2023-$6.25M–
Q1 FY2023Mar 31, 2023-$12.83M–
Q4 FY2022Dec 31, 2022-$9.31M–
Q3 FY2022Sep 30, 2022-$6.63M–
Q2 FY2022Jun 30, 2022-$24.77M-524.6%
Q1 FY2022Mar 31, 2022-$1.86M-126.7%
Q4 FY2021Dec 31, 2021-$2.84M–
Q3 FY2021Sep 30, 2021-$2.22M–
Q2 FY2021Jun 30, 2021$5.83M+125.0%
Q1 FY2021Mar 31, 2021$6.96M–
Q4 FY2020Dec 31, 2020-$3.21M–
Q3 FY2020Sep 30, 2020-$1.21M-137.5%
Q2 FY2020Jun 30, 2020$2.59M–
Q1 FY2020Mar 31, 2020-$3.78M–
Q4 FY2019Dec 31, 2019-$4.41M–
Q3 FY2019Sep 30, 2019$3.23M–
Q2 FY2019Jun 30, 2019-$7.79M–
Q1 FY2019Mar 31, 2019-$11.37M–
Q4 FY2018Dec 31, 2018-$9.27M–
Q3 FY2018Sep 30, 2018-$17.96M–
Q2 FY2018Jun 30, 2018-$13.91M–
Q1 FY2018Mar 31, 2018-$14.77M–
Q4 FY2017Dec 31, 2017-$8.15M–
Q3 FY2017Sep 30, 2017-$9.61M–
Q2 FY2017Jun 30, 2017-$8.22M–
Q1 FY2017Mar 31, 2017-$7.38M–
Q4 FY2016Dec 31, 2016-$10.84M–
Q3 FY2016Sep 30, 2016-$10.40M–

More Zevra Therapeutics figures

See a number that looks wrong?